The Impact of Re-Infection With COVID-19 on Human Immunity and Coping Strategies in The Post-Pandemic Era

Xinyuan Zhang

doi:10.62051/j3zhte26

Authors

Xinyuan Zhang

DOI:

https://doi.org/10.62051/j3zhte26

Keywords:

COVID-19 reinfection; Reinfection prevention; SARS-CoV-2; Vaccine efficacy; Plant-derived adjuvants.

Abstract

The COVID-19 pandemic, caused by SARS-CoV-2, has led to over 6.9 million deaths as of August 2024 as a significant global health threat. While advancement of vaccines and drugs targeting SARS-CoV-2 virus has reduced severe illness, reinfection remains a significant concern. This paper explores the impact of COVID-19 reinfection on human immunity and examines possible coping strategies, particularly the advancements in plant-derived adjuvants to enhance vaccine efficacy. The virus's ability to mutate, evade immune responses, and affect immune memory highlights the importance and potential effectiveness of treatments that prolong immunity response. Plant-derived adjuvants Advax and Matrix-M have been shown to improve long term immune responses by stimulating long-lasting antibodies and cytotoxic T-cell activation. Clinical trials have demonstrated efficacy and safety in preventing symptomatic and severe COVID-19, along plant-based adjuvants reducing reinfection risks. Future research could further focus on develop precising adjuvants’ formulations, exploring more plant-based compounds that could be apply in vaccine development, and conducting long-term studies to evaluate long-term immune durability and safety of the vaccines.

Downloads

Download data is not yet available.

References

[1] WHO. WHO Coronavirus Disease (COVID-19) Situation Dashboard. https:// covid 19. who. int/. Accessed 21 Nov 2021W. Strunk Jr., E.B. White, The Elements of Style, third ed., Macmillan, New York, 1979.

[2] Ranney, M. L., Griffeth, V., & Jha, A. K. (2020). Critical Supply Shortages—The Need for Ventilators and Personal Protective Equipment during the COVID-19 Pandemic. New England Journal of Medicine, 382(18), 1741-1748. DOI: 10.1056/NEJMp2006141

[3] Hadley, E., Yoo, Y. J., Patel, S., Zhou, A., Laraway, B., Wong, R., Preiss, A., Chew, R., Davis, H., Chute, C. G., Pfaff, E. R., Loomba, J., Haendel, M., Hill, E., Moffitt, R., & N3C and RECOVER consortia. (n.d.). SARS-CoV-2 reinfection is preceded by unique biomarkers and related to initial infection timing and severity: An N3C RECOVER EHR-based cohort study.

[4] WHO. Tracking SARS-CoV-2 variants. WHO. https:// www. who. int/ zh/ activ ities/ track ing- SARS- CoV-2- varia nts.

[5] Röltgen, K., Nielsen, S. C. A., Silva, O., Younes, S. F., Zaslavsky, M., Costales, C., Yang, F., Wirz, O. F., Solis, D., Hoh, R. A., Wang, A., Arunachalam, P. S., Colburg, D., Zhao, S., Haraguchi, E., Lee, A. S., Shah, M. M., Manohar, M., Chang, I., ... Boyd, S. D. (2022). Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell. https://doi.org/10.1016/j.cell.2022.01.018

[6] Pilz, S., Theiler-Schwetz, V., Trummer, C., Krause, R., & Ioannidis, J. P. A. (2022). SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity. Environmental Research, 209, 112911. https://doi.org/10.1016/j.envres.2022.112911

[7] Bourgonje, A. R., Abdulle, A. E., Timens, W., Hillebrands, J. L., Navis, G. J., Gordijn, S. J., Bolling, M. C., Dijkstra, G., Voors, A. A., Osterhaus, A. D. M. E., van der Voort, P. H. J., Mulder, D. J., & van Goor, H. (2020). Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). The Journal of Pathology, 251(3), 228–248. https://doi.org/10.1002/path.5471

[8] Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., Zhang, X., Muruato, A. E., Zou, J., Fontes-Garfias, C. R., Mirchandani, D., Scharton, D., Bilello, J. P., Ku, Z., An, Z., Kalveram, B., Freiberg, A. N., Menachery, V. D., Xie, X., Plante, K. S., Weaver, S. C., & Shi, P.-Y. (2020). Spike mutation D614G alters SARS-CoV-2 fitness. Nature, 586(7837), 783-789. https://doi.org/10.1038/s41586-020-2895-3

[9] Weisblum, Y. et al. Escape from neutralizing antibodies by SARS- CoV-2 spike protein variants. eLife https:// doi.org/10.7554/eLife.61312 (2020).

[10] McCarthy, K. R. et al. Recurrent deletions in the SARS- CoV-2 spike glycoprotein drive antibody escape. Science 371, 1139–1142 (2021).

[11] Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, Peacock, S. J., & Robertson, D. L. (2021). SARS-CoV-2 variants, spike mutations and immune escape. Nature Reviews Microbiology, 19(7), 409–424. https://doi.org/10.1038/s41579-021-00573-0

[12] Matyushenko, V., Isakova-Sivak, I., Kudryavtsev, I., Goshina, A., Chistyakova, A., Stepanova, E., Prokopenko, P., Sychev, I., & Rudenko, L. (2021). Detection of IFNγ-secreting CD4+ and CD8+ memory T cells in COVID-19 convalescents after stimulation of peripheral blood mononuclear cells with live SARS-CoV-2. Viruses, 13(8), 1490. https://doi.org/10.3390/v13081490

[13] J.M. Dan, J. Mateus, Y. Kato, K.M. Hastie, E.D. Yu, C.E. Faliti, et al., Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection, Science (2021).

[14] To KK, Hung IF, Ip JD, et al. COVID-19 re-infection by a phylogeneti-cally distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin Infect Dis. 2020. https:// doi. org/ 10. 1093/ cid/ ciaa1 275.

[15] Tabarsi, P., Anjidani, N., Shahpari, R., Mardani, M., Sabzvari, A., Yazdani, B., Kafi, H., Fallah, N., Ebrahimi, A., Taheri, A., Petrovsky, N., & Barati, S. (2022). Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2–adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: A phase 3 randomized placebo-controlled trial. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2022.09.001

[16] Toback, S., Galiza, E., Cosgrove, C., Galloway, J., Goodman, A. L., Swift, P. A., Rajaram, S., Graves-Jones, A., Edelman, J., Burns, F., Minassian, A. M., Cho, I., Kumar, L., Plested, J. S., Rivers, E. J., Robertson, A., Dubovsky, F., Glenn, G., & Heath, P. T., 2019nCoV-302 Study Group. (2021). Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: An exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine, 9(11), 1270–1280. https://doi.org/10.1016/S2213-2600(21)00409-4